Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
The Future MSL
Summary
In this episode, Eddie Power joins to discuss the future landscape of the Medical Science Liaison (MSL) role. The conversation delves into emerging trends, including the integration of analytics to enhance MSL functions and the evolving responsibilities that may lead to new titles. Eddie explores how data delivery and strategy will shape MSL activities, alongside expanding stakeholder engagement. The episode also provides insights on preparing current MSLs for upcoming changes and offers advice to MSL leaders on fostering diversity, equity, and inclusion within their teams. The discussion wraps up with expressions of gratitude and appreciation for the listeners.
Learn more about…
π What factors will affect the MSL job and its trajectory into the future
π What credentials will be necessary for the future MSL and what might change
π What is on the horizon that makes the MSL role better (or worse) in the future
π Is the future of the MSL role in jeopardy at all due to AI and artificial intelligence
π Will new titles and responsibilities emerge for the MSL of the future
π Will the MSL of the future be more involved with the patient
medical science liaison, MSL role evolution, future of MSL, analytics in MSL, MSL diversity
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary